Biapenem cas: 120410-24-4

CAS NO: 120410-24-4
Biapenem
Description Review
Description

Biapenem, also known as AKSci M048 (CAS: 120410-24-4), is a carbapenem antibiotic that is used to treat bacterial infections. This product works by inhibiting bacterial cell wall synthesis, which is necessary for the survival and replication of bacteria.

Chemical name: (4R,5S,6S)-3-{[(3S,5S)-5-(aminomethyl)-7-[[(2S,3R)-2-hydroxy-3-[[(1-methyl-1H-tetrazol-5-yl)sulfonyl]amino]butanoyl]amino]-3-propyl-1-azabicyclo[3.2.0]hept-2-en-4-yl]carbonyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Molecular formula: C22H28N10O8S2

Formula weight: 636.69 g/mol

CAS No: 120410-24-4

Top ten keywords from Google and Synonyms:

  1. Antibiotic treatment
  2. Carbapenem medication
  3. Biapenem powder
  4. CAS 120410-24-4
  5. Bacterial infections
  6. Gram-positive bacteria
  7. Inhibits cell wall synthesis
  8. Broad-spectrum antibiotic
  9. Drug-resistant bacteria
  10. Pseudomonas aeruginosa

Synonyms: AKSci M048, (4R,5S,6S)-3-{[(3S,5S)-5-(aminomethyl)-7-[[(2S,3R)-2-hydroxy-3-[[(1-methyl-1H-tetrazol-5-yl)sulfonyl]amino]butanoyl]amino]-3-propyl-1-azabicyclo[3.2.0]hept-2-en-4-yl]carbonyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Health benefits of Biapenem:

The primary health benefit of Biapenem is its ability to inhibit bacterial cell wall synthesis, which is necessary for the survival and replication of bacteria. By doing so, this medication can help treat bacterial infections and improve outcomes for patients with these infections.

Potential effects of Biapenem:

Biapenem works by inhibiting bacterial cell wall synthesis, which is necessary for the survival and replication of bacteria. In clinical trials, this medication has demonstrated significant antibacterial activity, including against drug-resistant strains of bacteria. Additionally, Biapenem may have the potential to be used as a broad-spectrum antibiotic, meaning it is effective against a wide range of different types of bacteria.

Product mechanism:

Biapenem works by inhibiting bacterial cell wall synthesis, which is necessary for the survival and replication of bacteria. By doing so, this medication can help treat bacterial infections and improve outcomes for patients with these infections. Additionally, Biapenem has a unique chemical structure that allows it to be effective against a wide range of different types of bacteria, making it a promising agent for the treatment of drug-resistant infections.

Safety:

Biapenem is generally considered safe when taken as directed by a healthcare provider. However, like any medication, it does carry some risks and potential side effects. Before taking this medication, patients should discuss their medical history and any current medications with their healthcare provider to ensure that it is safe for them to take.

Side effects of Biapenem:

Common side effects of Biapenem include gastrointestinal symptoms such as nausea and diarrhea, as well as skin rash and headache. More serious side effects are rare, but may include allergic reactions and changes in liver function tests. Patients who experience any of these symptoms while taking this medication should contact their healthcare provider immediately.

Dosing information:

The recommended dose of Biapenem varies depending on the patient's medical history and condition. It is important for patients to follow their healthcare provider's instructions regarding dosing and administration of this medication.

Conclusion:

Biapenem is a carbapenem antibiotic that is used to treat bacterial infections. By inhibiting bacterial cell wall synthesis, this medication can help treat these infections and improve outcomes for patients with them. While generally considered safe, this medication does carry some risks and potential side effects, so patients should discuss their medical history and any current medications with their healthcare provider before taking it. Overall, Biapenem is a promising medication that may hold

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code